Canadian journal of anaesthesia = Journal canadien d'anesthésie
-
Editorial Comment
The aging anesthesiologist: Are we asking the right question?
-
Recombinant activated factor VII (rFVIIa) is a pro-hemostatic drug that is approved for treatment of bleeding in hemophilia patients, but it is frequently used off-label in non-hemophiliacs. The purpose of this study was to determine if the off-label use of rFVIIa is expanding and whether this poses a net harm to patients. ⋯ The off-label use of rFVIIa in Canada remains stable. Since severity of bleeding is prognostically important, the benefits of rapidly gaining control of bleeding that is non-responsive to conventional therapies may at times warrant the use of potent hemostatic drugs with established risk profiles, such as rFVIIa.
-
Historical Article
From the Journal archives: Cyclopropane: induction and recovery with a bang!
To review the history of the early development of cyclopropane ⋯ The phenomenal success of cyclopropane in over 40 years of clinical use resulted from a lucky, but incorrect, hypothesis that it was a toxic contaminant.